UA90130C2 - Аморфный лерканидипина гидрохлорид и фармацевтическая композиция на его основе - Google Patents

Аморфный лерканидипина гидрохлорид и фармацевтическая композиция на его основе

Info

Publication number
UA90130C2
UA90130C2 UAA200709786A UAA200709786A UA90130C2 UA 90130 C2 UA90130 C2 UA 90130C2 UA A200709786 A UAA200709786 A UA A200709786A UA A200709786 A UAA200709786 A UA A200709786A UA 90130 C2 UA90130 C2 UA 90130C2
Authority
UA
Ukraine
Prior art keywords
amorphous lercanidipine
pharmaceutical composition
composition based
pure
lercanidipine hydrochloride
Prior art date
Application number
UAA200709786A
Other languages
English (en)
Ukrainian (uk)
Inventor
Амедео Леонарди
Джианни Мотта
Фабио Берлати
Original Assignee
Рекордати Айеленд Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36585434&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA90130(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Рекордати Айеленд Лимитед filed Critical Рекордати Айеленд Лимитед
Publication of UA90130C2 publication Critical patent/UA90130C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B63/00—Purification; Separation; Stabilisation; Use of additives
    • C07B63/04—Use of additives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
    • C07D211/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Данное изобретение касается практически чистого аморфного лерканидипина гидрохлорида, который является чистым по меньшей мере на 95 %, преимущественно чистым по меньшей мере примерно на 97 %, еще более преимущественно чистым по меньшей мере примерно на 99 % и наиболее преимущественно чистым по меньшей мере примерно на 99,5 %. Данное изобретение также касается способов получения практически чистого аморфного лерканидипина и фармацевтических композиций, которые содержат практически чистый аморфный лерканидипин.
UAA200709786A 2005-02-25 2006-02-24 Аморфный лерканидипина гидрохлорид и фармацевтическая композиция на его основе UA90130C2 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US65683605P 2005-02-25 2005-02-25

Publications (1)

Publication Number Publication Date
UA90130C2 true UA90130C2 (ru) 2010-04-12

Family

ID=36585434

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200709786A UA90130C2 (ru) 2005-02-25 2006-02-24 Аморфный лерканидипина гидрохлорид и фармацевтическая композиция на его основе

Country Status (32)

Country Link
US (1) US7820701B2 (ru)
EP (1) EP1856051B1 (ru)
JP (1) JP2008531515A (ru)
KR (1) KR20070105979A (ru)
CN (1) CN101124204A (ru)
AR (1) AR052918A1 (ru)
AU (1) AU2006218026B9 (ru)
BR (1) BRPI0608138A2 (ru)
CA (1) CA2598016A1 (ru)
CY (1) CY1122429T1 (ru)
DK (1) DK1856051T3 (ru)
EA (1) EA014383B1 (ru)
ES (1) ES2339213T3 (ru)
HR (1) HRP20192302T1 (ru)
HU (1) HUE046910T2 (ru)
IL (1) IL184349A0 (ru)
LT (1) LT1856051T (ru)
ME (1) ME03659B (ru)
MX (1) MX2007010093A (ru)
MY (1) MY142129A (ru)
NO (1) NO344559B1 (ru)
NZ (1) NZ556667A (ru)
PE (1) PE20061014A1 (ru)
PL (1) PL1856051T3 (ru)
PT (1) PT1856051T (ru)
RS (1) RS59654B1 (ru)
SI (1) SI1856051T1 (ru)
TW (1) TW200640861A (ru)
UA (1) UA90130C2 (ru)
UY (1) UY29401A1 (ru)
WO (1) WO2006089787A1 (ru)
ZA (1) ZA200708127B (ru)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60326961D1 (de) * 2002-07-26 2009-05-14 Novartis Vaccines & Diagnostic Modifizierte kleine irns moleküle und methoden zu deren anwendung
AR052918A1 (es) 2005-02-25 2007-04-11 Recordati Ireland Ltd Clorhidrato de lercanidipina amorfo
CA2622683A1 (en) 2005-09-16 2007-03-22 Glenmark Pharmaceuticals Limited Polymorphic form of lercanidipine hydrochloride and process for the preparation thereof
DK2046745T3 (da) * 2006-08-04 2014-01-20 Recordati Ireland Ltd Fremgangsmåde til fremstilling af amorft lercanidipin-hydrochlorid
EP2101771A2 (en) * 2006-12-06 2009-09-23 Torrent Pharmaceuticals Ltd Stable lercanidipine formulation
WO2008107797A2 (en) * 2007-03-05 2008-09-12 Actavis Group Ptc Ehf Lercanidipine hydrochloride polymorphs and an improved process for preparation of 1,1,n-trimethyl-n-(3,3-diphenylpropyl)-2-aminoethyl acetoacetate
US8461172B2 (en) * 2009-05-12 2013-06-11 Corcept Therapeutics, Inc. Solid forms and process for preparing
DE102010005124A1 (de) * 2010-01-19 2012-03-01 Stada Arzneimittel Ag Feste pharmazeutische Zusammensetzung umfassend Lercanidipin
EP2444394A1 (en) 2010-10-21 2012-04-25 Alembic Pharmaceuticals Limited Process for the preparation of amorphous form of lercanidipine HCI
CN102531999B (zh) * 2011-12-16 2014-02-26 华润赛科药业有限责任公司 无定形盐酸乐卡地平及其制备方法
CN102558032B (zh) * 2011-12-16 2014-02-26 华润赛科药业有限责任公司 一种无定形盐酸乐卡地平及其制备方法
CN102600146B (zh) * 2012-04-11 2014-10-08 兆科药业（合肥）有限公司 一种盐酸乐卡地平和氯沙坦钾复方制剂及其制备方法
IN2013MU02828A (ru) * 2013-08-29 2015-07-03 Cadila Healthcare Ltd

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8403866D0 (en) * 1984-02-14 1984-03-21 Recordati Chem Pharm Diphenylalkylaminoalkyl esters
IT1274480B (it) 1995-05-12 1997-07-17 Recordati Chem Pharm Procedimento migliorato per la preparazione della lercanidipina cloridrato
US5767136A (en) 1995-05-12 1998-06-16 Recordati, S.A. Chemical And Pharmaceutical Company 1,4-Dihydropyridines useful for prevention or reduction of atherosclerotic lesions on arterial walls
US5696139A (en) 1995-05-12 1997-12-09 Recordati S.A., Chemical And Pharmaceutical Company Use of S-enantiomers of 1,4-dihydropyridine derivatives for treating heart failure
ITMI20011727A1 (it) 2001-08-06 2003-02-06 Recordati Ind Chimica E Farma Solvati della lercanidipina cloridrato e nuove forme cristalline della lercanidipina cloridrato ottenute da essi
ITMI20011726A1 (it) 2001-08-06 2003-02-06 Recordati Ind Chimica E Farma Forme polimorfe della lercanidipina cloridrato
US6852737B2 (en) 2001-08-06 2005-02-08 Recordati Ireland Limited Crude and crystalline forms of lercanidipine hydrochloride
US20030069285A1 (en) 2001-08-06 2003-04-10 Recordati Ireland Limited Novel solvate and crystalline forms of lercanidipine hydrochloride
US20030180355A1 (en) 2001-10-16 2003-09-25 Amedeo Leonardi Combination therapy for hypertension
JP4749660B2 (ja) * 2002-10-16 2011-08-17 武田薬品工業株式会社 安定な固形製剤
US20040147566A1 (en) 2002-10-16 2004-07-29 Amedeo Leonardi Lisinopril/lercanidipine combination therapy
US20040198789A1 (en) 2003-02-28 2004-10-07 Recordati Ireland Limited Lercanidipine/ARB/diuretic therapeutic combinations
TW200613275A (en) 2004-08-24 2006-05-01 Recordati Ireland Ltd Lercanidipine salts
TW200616681A (en) 2004-10-05 2006-06-01 Recordati Ireland Ltd Lercanidipine capsules
KR100651212B1 (ko) 2004-10-27 2006-12-01 제일약품주식회사 무정형 레르카니디핀의 제조방법
AR052918A1 (es) 2005-02-25 2007-04-11 Recordati Ireland Ltd Clorhidrato de lercanidipina amorfo
CA2622683A1 (en) 2005-09-16 2007-03-22 Glenmark Pharmaceuticals Limited Polymorphic form of lercanidipine hydrochloride and process for the preparation thereof
WO2007054969A2 (en) 2005-09-21 2007-05-18 Torrent Pharmaceuticals Limited Process for the preparation of lercanidipine and amorphous form of lercanidipine hydrochloride
DK2046745T3 (da) 2006-08-04 2014-01-20 Recordati Ireland Ltd Fremgangsmåde til fremstilling af amorft lercanidipin-hydrochlorid

Also Published As

Publication number Publication date
NO20074874L (no) 2007-11-26
CA2598016A1 (en) 2006-08-31
TW200640861A (en) 2006-12-01
DK1856051T3 (da) 2020-01-02
HUE046910T2 (hu) 2020-04-28
CN101124204A (zh) 2008-02-13
HRP20192302T1 (hr) 2020-03-06
CY1122429T1 (el) 2021-01-27
AR052918A1 (es) 2007-04-11
RS59654B1 (sr) 2020-01-31
AU2006218026A1 (en) 2006-08-31
EP1856051A1 (en) 2007-11-21
UY29401A1 (es) 2006-06-30
ZA200708127B (en) 2008-11-26
BRPI0608138A2 (pt) 2009-11-17
PE20061014A1 (es) 2006-10-03
US7820701B2 (en) 2010-10-26
AU2006218026B2 (en) 2009-04-02
PT1856051T (pt) 2020-01-07
ES2339213T1 (es) 2010-05-18
US20060211742A1 (en) 2006-09-21
SI1856051T1 (sl) 2020-02-28
NZ556667A (en) 2009-10-30
ME03659B (me) 2021-01-20
JP2008531515A (ja) 2008-08-14
EA200701687A1 (ru) 2008-02-28
EP1856051B1 (en) 2019-11-13
MY142129A (en) 2010-09-30
PL1856051T3 (pl) 2020-05-18
EA014383B1 (ru) 2010-10-29
MX2007010093A (es) 2007-10-12
AU2006218026B9 (en) 2011-10-27
IL184349A0 (en) 2007-10-31
WO2006089787A1 (en) 2006-08-31
LT1856051T (lt) 2020-01-10
KR20070105979A (ko) 2007-10-31
ES2339213T3 (es) 2020-05-28
NO344559B1 (no) 2020-02-03

Similar Documents

Publication Publication Date Title
UA90130C2 (ru) Аморфный лерканидипина гидрохлорид и фармацевтическая композиция на его основе
ME03786B (me) Farmaceutske kompozicije amorfnog oblika n-[2,4-bis(1,1-dimetiletil)-5-hidroksifenil]-1,4-dihidro-4-oksohinolin-3-karboksamida
TNSN07235A1 (en) Crystalline forms of (r)-8-chloro-1-methyl- 2,3,4,5-tetrahydro-1h-3-benzazepine hydrochloride
AP1830A (en) Polymorphous form of rimonabant, preparation method and pharmaceutical compositions containing same.
PL1695709T3 (pl) Postać krystaliczna gamma-d chlorowodorku iwabradyny, sposób jej wytwarzania i kompozycje farmaceutyczne zawierające tę postać
SI2210872T1 (sl) Nova kristalinična oblika iii agomelatina, postopek za njeno pripravo in farmacevtski sestavki, ki jo vsebujejo
PT1811957E (pt) Composição farmacêutica sólida contendo cloridrato de donepezil
WO2006056696A3 (fr) 2-alcoxy-3,4,5-trihydroxy-alkylamides, leur preparation, compositions les contenant et utilisation
MX2008001560A (es) Nuevos compuestos analogos de la camptotecina, un procedimiento para su preparacion y composiciones farmaceuticas que los contienen.
IL164440A0 (en) New pharmaceutical composition containing fibanserin polymorph a
RS11304A (en) Novel crystalline polymorphic forms of lercanidipine hydrochloride and process for their preparation
TW200640860A (en) Lercanidipine free base
MXPA04005307A (es) Clorhidrato de venlafaxina en forma de monohidrato y sus metodos de preparacion.
EP1852119A4 (en) PHARMACEUTICAL PREPARATION CONTAINING PHENOXAZINIUM DERIVATIVE AS ACTIVE INGREDIENT
EP1406614A4 (en) CARVEDILOLPOLYMORPH
HK1093721A1 (en) Ibopamine maleate, method for preparing it and pharmaceutical compositions containing it